Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.26 Million USD | -80.09% |
| 2022 | 67.3 Million USD | -21.77% |
| 2021 | 86.02 Million USD | -50.47% |
| 2020 | 173.69 Million USD | 16.91% |
| 2019 | 148.57 Million USD | 2.86% |
| 2018 | 144.44 Million USD | 45.11% |
| 2017 | 99.54 Million USD | 83.6% |
| 2016 | 54.21 Million USD | 206.91% |
| 2015 | 17.66 Million USD | -27.09% |
| 2014 | 24.23 Million USD | 139.13% |
| 2013 | -61.92 Million USD | -46.84% |
| 2012 | -42.16 Million USD | -11.7% |
| 2011 | -37.75 Million USD | 5.91% |
| 2010 | -40.12 Million USD | -1099.08% |
| 2009 | 4.01 Million USD | 115.53% |
| 2008 | -25.86 Million USD | -35.77% |
| 2007 | -19.04 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 18.21 Million USD | 528.77% |
| 2024 Q3 | 40.84 Million USD | 124.25% |
| 2024 Q1 | -4.24 Million USD | -122.37% |
| 2023 Q2 | -17.58 Million USD | -298.16% |
| 2023 Q1 | 8.87 Million USD | -74.15% |
| 2023 FY | 13.4 Million USD | -80.09% |
| 2023 Q4 | 18.98 Million USD | 133.34% |
| 2023 Q3 | 8.13 Million USD | 146.27% |
| 2022 Q4 | 34.33 Million USD | 1844.17% |
| 2022 FY | 67.3 Million USD | -21.77% |
| 2022 Q3 | 1.76 Million USD | -84.44% |
| 2022 Q1 | 17.33 Million USD | 184.19% |
| 2022 Q2 | 11.34 Million USD | -34.53% |
| 2021 Q2 | 34.11 Million USD | 158.16% |
| 2021 FY | 86.02 Million USD | -50.47% |
| 2021 Q4 | 6.09 Million USD | -81.3% |
| 2021 Q1 | 13.21 Million USD | -69.27% |
| 2021 Q3 | 32.6 Million USD | -4.42% |
| 2020 Q3 | 56.14 Million USD | 23.25% |
| 2020 FY | 173.69 Million USD | 16.91% |
| 2020 Q1 | 29.01 Million USD | -28.92% |
| 2020 Q2 | 45.54 Million USD | 57.0% |
| 2020 Q4 | 42.99 Million USD | -23.41% |
| 2019 Q2 | 42.59 Million USD | 67.52% |
| 2019 FY | 148.57 Million USD | 2.86% |
| 2019 Q1 | 25.42 Million USD | -36.2% |
| 2019 Q4 | 40.81 Million USD | 2.74% |
| 2019 Q3 | 39.72 Million USD | -6.74% |
| 2018 Q3 | 37.47 Million USD | 4.91% |
| 2018 Q2 | 35.72 Million USD | 13.78% |
| 2018 Q1 | 31.39 Million USD | -8.59% |
| 2018 Q4 | 39.85 Million USD | 6.35% |
| 2018 FY | 144.44 Million USD | 45.11% |
| 2017 Q4 | 34.34 Million USD | 53.72% |
| 2017 FY | 99.54 Million USD | 83.6% |
| 2017 Q3 | 22.34 Million USD | -14.29% |
| 2017 Q2 | 26.06 Million USD | 55.27% |
| 2017 Q1 | 16.78 Million USD | 3.02% |
| 2016 FY | 54.21 Million USD | 206.91% |
| 2016 Q2 | 10.44 Million USD | 96.31% |
| 2016 Q4 | 16.29 Million USD | -17.86% |
| 2016 Q3 | 19.83 Million USD | 90.03% |
| 2016 Q1 | 5.31 Million USD | -22.35% |
| 2015 Q4 | 6.84 Million USD | 58.95% |
| 2015 FY | 17.66 Million USD | -27.09% |
| 2015 Q3 | 4.3 Million USD | 40.08% |
| 2015 Q2 | 3.07 Million USD | -10.32% |
| 2015 Q1 | 3.43 Million USD | -27.47% |
| 2014 Q2 | 3.75 Million USD | 127.98% |
| 2014 Q1 | -13.42 Million USD | -18.18% |
| 2014 Q4 | 4.72 Million USD | -83.79% |
| 2014 FY | 24.23 Million USD | 139.13% |
| 2014 Q3 | 29.16 Million USD | 676.54% |
| 2013 FY | -61.92 Million USD | -46.84% |
| 2013 Q4 | -11.35 Million USD | 33.87% |
| 2013 Q3 | -17.17 Million USD | -10.96% |
| 2013 Q2 | -15.47 Million USD | 13.56% |
| 2013 Q1 | -17.9 Million USD | -40.52% |
| 2012 Q2 | -9.25 Million USD | -17.5% |
| 2012 Q1 | -7.87 Million USD | 60.86% |
| 2012 Q3 | -12.29 Million USD | -32.76% |
| 2012 Q4 | -12.74 Million USD | -3.69% |
| 2012 FY | -42.16 Million USD | -11.7% |
| 2011 Q3 | -9.91 Million USD | -18.09% |
| 2011 Q4 | -20.13 Million USD | -103.03% |
| 2011 Q1 | -9.19 Million USD | 52.55% |
| 2011 FY | -37.75 Million USD | 5.91% |
| 2011 Q2 | -8.39 Million USD | 8.72% |
| 2010 Q4 | -19.38 Million USD | 0.0% |
| 2010 FY | -40.12 Million USD | -1099.08% |
| 2009 FY | 4.01 Million USD | 115.53% |
| 2009 Q4 | -13.74 Million USD | 0.0% |
| 2008 FY | -25.86 Million USD | -35.77% |
| 2007 FY | -19.04 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Theratechnologies Inc. | -10.62 Million USD | 50.419% |
| Harrow Health, Inc. | 580 Thousand USD | 1008.448% |
| Dynavax Technologies Corporation | -37.02 Million USD | 85.77% |
| Biofrontera Inc. | -22.67 Million USD | 76.765% |
| Cronos Group Inc. | -81.37 Million USD | 93.525% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -12.083% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.521% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 86.543% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 141.712% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 15.164% |
| Radius Health, Inc. | -3.92 Million USD | -34.242% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -49.4% |
| DURECT Corporation | -36.88 Million USD | 85.715% |
| ProPhase Labs, Inc. | -21.61 Million USD | 75.621% |
| Safety Shot Inc | -12.18 Million USD | 56.755% |
| Phibro Animal Health Corporation | 53.31 Million USD | 109.883% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -109.485% |
| Alvotech | -354.86 Million USD | 98.515% |
| Assertio Holdings, Inc. | -243.53 Million USD | 97.836% |
| Rockwell Medical, Inc. | -6.67 Million USD | 21.004% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -10.108% |
| Procaps Group S.A. | 52.32 Million USD | 110.07% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 96.694% |
| SCYNEXIS, Inc. | 72.66 Million USD | 107.251% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -0.285% |
| Viatris Inc. | 766.2 Million USD | 100.688% |
| OptiNose, Inc. | -22.74 Million USD | 76.838% |
| SIGA Technologies, Inc. | 83.62 Million USD | 106.301% |
| Tilray Brands, Inc. | -174.74 Million USD | 96.985% |
| PetIQ, Inc. | 60.01 Million USD | 108.779% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -10.108% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.1% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -21.509% |
| Alimera Sciences, Inc. | -1.47 Million USD | -258.192% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 103.156% |
| Silver Spike Investment Corp. | 7.34 Million USD | 171.784% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 10.579% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 142.068% |
| Journey Medical Corporation | -2.07 Million USD | -154.173% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 61.307% |
| Alpha Teknova, Inc. | -35.56 Million USD | 85.184% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 66.211% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 156.468% |
| PainReform Ltd. | -9.58 Million USD | 45.023% |
| Cosmos Health Inc. | -21.83 Million USD | 75.865% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.178% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 38.179% |
| Embecta Corp. | 221.5 Million USD | 102.379% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -11.237% |
| Talphera, Inc. | -16.88 Million USD | 68.802% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 106.01% |
| Incannex Healthcare Limited | -30.04 Million USD | 82.461% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 73.721% |
| Shineco, Inc. | -17.06 Million USD | 69.126% |
| Procaps Group, S.A. | 38.97 Million USD | 113.52% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 111.218% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 65.111% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.445% |
| Alvotech | -354.86 Million USD | 98.515% |
| Hempacco Co., Inc. | -8.81 Million USD | 40.208% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 109.857% |
| Bright Green Corporation | -8.89 Million USD | 40.74% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.613% |
| Kamada Ltd. | 10.06 Million USD | 152.355% |
| Indivior PLC | -4 Million USD | -31.725% |
| Evoke Pharma, Inc. | -7.43 Million USD | 29.093% |
| Flora Growth Corp. | -50.35 Million USD | 89.536% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 73.721% |
| Evolus, Inc. | -49.23 Million USD | 89.298% |
| HUTCHMED (China) Limited | 18.37 Million USD | 128.675% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.675% |
| Akanda Corp. | -10.05 Million USD | 47.579% |